Waldenstrom macroglobulinemia is considered the most common subtype of lymphoplasmacytic lymphoma, as per the current WHO classification. Although a rare blood cancer, the incidence of Waldenstrom’s macroglobulinemia is strongly influenced by sex, age, race, and ethnicity. It is reported that the incidence of Waldenstrom’s macroglobulinemia is two times higher in men than in women in the United States. Existing treatments for this B-cell lymphoma are often linked to significant side effects, indicating the need for therapies with improved safety profiles and better tolerability.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Waldenstrom’s macroglobulinemia.
Waldenstrom’s macroglobulinemia is treated by a combination of drugs, procedures, and other therapies. Chemotherapy, radiation therapy, and plasmapheresis are common treatment options for this rare disease. Steroids such as dexamethasone or prednisolone are often prescribed to increase the efficiency of chemotherapy agents. However, certain patients develop resistance to current therapies, leading to disease progression or relapse. Thus, there is a critical need to develop novel drugs that target alternative pathways or overcome resistance mechanisms.
Sponsored by Cellectar Biosciences, Inc., the objective of this Phase 2, open-label, multicenter study is to evaluate Iopofosine I 131 (CLR 131), a targeted radiotherapeutic, in patients with relapsed or refractory (R/R) B-cell cancers and in an expansion group of patients with Waldenstrom macroglobulinemia. The study is expected to be completed by December 2026 and has an estimated 120 participants.
This product will be delivered within 3-5 business days.
Report Coverage
Waldenstrom’s Macroglobulinemia Drug Pipeline Insight Report by the publisher gives comprehensive insights into Waldenstrom’s macroglobulinemia drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Waldenstrom’s macroglobulinemia. The report includes the analysis of over 100 pipeline drugs and 50+ companies. The Waldenstrom’s macroglobulinemia pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from Waldenstrom’s Macroglobulinemia.The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Waldenstrom’s macroglobulinemia.
Waldenstrom’s Macroglobulinemia Drug Pipeline Outlook
Waldenstrom’s macroglobulinemia refers to a type of non-Hodgkin lymphoma that affects plasma cells and lymphoplasmacytoid cells (types of white blood cells). It is caused by DNA changes in the white blood cells that trigger them to multiply quickly and live longer than healthy cells. Common symptoms of this rare, slow-growing blood cancer include extreme tiredness, nosebleeds, frequent infections, and unintentional weight loss, among others.Waldenstrom’s macroglobulinemia is treated by a combination of drugs, procedures, and other therapies. Chemotherapy, radiation therapy, and plasmapheresis are common treatment options for this rare disease. Steroids such as dexamethasone or prednisolone are often prescribed to increase the efficiency of chemotherapy agents. However, certain patients develop resistance to current therapies, leading to disease progression or relapse. Thus, there is a critical need to develop novel drugs that target alternative pathways or overcome resistance mechanisms.
Waldenstrom’s Macroglobulinemia - Drug Pipeline Therapeutic Assessment
This section of the report covers the analysis of Waldenstrom’s macroglobulinemia drugs based on several segmentations including:By Phase
- Late-Stage Products (Phase 3 and Phase 4)
- Mid-Stage Products (Phase 2)
- Early-Stage Products (Phase I)
- Preclinical and Discovery Stage Products
By Drug Class
- Recombinant Fusion Proteins
- Small Molecule
- Monoclonal Antibody
- Peptide
- Polymer
- Gene Therapy
By Route of Administration
- Oral
- Parenteral
- Others
Waldenstrom’s Macroglobulinemia - Pipeline Assessment Segmentation, By Phases
The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total clinical trials for Waldenstrom’s macroglobulinemia.Waldenstrom’s Macroglobulinemia - Pipeline Assessment Segmentation, By Drug Classes
The drug molecule categories covered under Waldenstrom’s macroglobulinemia pipeline analysis include recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymer, and gene therapy. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Waldenstrom macroglobulinemia.Waldenstrom’s Macroglobulinemia Clinical Trials Therapeutic Assessment - Competitive Dynamics
The report for Waldenstrom’s macroglobulinemia drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in Waldenstrom’s macroglobulinemia clinical trials:- Merck Sharp & Dohme LLC
- Cellectar Biosciences, Inc.
- Schrodinger Inc.
- Eli Lilly and Company
- Gilead Sciences
- AstraZeneca
Waldenstrom’s Macroglobulinemia - Emerging Drugs Profile
Major drugs currently in the drug pipeline are as follows:
Drug: Iopofosine I 131 (CLR 131
)Sponsored by Cellectar Biosciences, Inc., the objective of this Phase 2, open-label, multicenter study is to evaluate Iopofosine I 131 (CLR 131), a targeted radiotherapeutic, in patients with relapsed or refractory (R/R) B-cell cancers and in an expansion group of patients with Waldenstrom macroglobulinemia. The study is expected to be completed by December 2026 and has an estimated 120 participants.
Drug: SGR-1505
Schrödinger, Inc. is conducting a Phase 1 dose-escalation study aimed at evaluating an oral inhibitor of MALT1 called SGR-1505 in participants with B-cell malignancies including Waldenstrom macroglobulinemia. The interventional study has enrolled an estimated 52 subjects and is expected to be completed by March 2026.Reasons To Buy This Report
The Waldenstrom’s Macroglobulinemia Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for Waldenstrom’s macroglobulinemia. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into market trends, regulatory environments, and potential growth opportunities within Waldenstrom’s macroglobulinemia pipeline insights.Key Questions Answered in the Waldenstrom’s Macroglobulinemia - Pipeline Insight Report
- What is the current landscape of Waldenstrom’s macroglobulinemia pipeline drugs?
- How many companies are developing Waldenstrom’s macroglobulinemia drugs?
- How many phase III and phase IV drugs are currently present in Waldenstrom’s macroglobulinemia pipeline drugs?
- Which companies/institutions are leading Waldenstrom’s macroglobulinemia drug development?
- What is the efficacy and safety profile of Waldenstrom’s macroglobulinemia pipeline drugs?
- What are the opportunities and challenges present in the Waldenstrom’s macroglobulinemia drug pipeline landscape?
- Which company is conducting major trials for Waldenstrom’s macroglobulinemia drugs?
- What geographies are covered for Waldenstrom’s macroglobulinemia clinical trials?
- What are emerging trends in Waldenstrom’s macroglobulinemia clinical trials?
This product will be delivered within 3-5 business days.
Table of Contents
1 Preface
3 Overview of Waldenstrom’s Macroglobulinemia
4 Patient Profile: Waldenstrom’s Macroglobulinemia
5 Waldenstrom’s Macroglobulinemia: Epidemiology Snapshot
6 Waldenstrom’s Macroglobulinemia: Market Dynamics
7 Waldenstrom’s Macroglobulinemia: Key Facts Covered
8 Waldenstrom’s Macroglobulinemia, Drug Pipeline Assessment
9 Drug Pipeline Comparative Analysis
10 Waldenstrom’s Macroglobulinemia Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
11 Waldenstrom’s Macroglobulinemia Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
12 Waldenstrom’s Macroglobulinemia Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
13 Waldenstrom’s Macroglobulinemia Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
14 Waldenstrom’s Macroglobulinemia, Key Drug Pipeline Companies
